{"schema_version":"1","generated_at":"2026-11-03T09:04:27.761Z","data_as_of":null,"url":"https://www.findmykol.com/kol/sherleen-chen","json_url":"https://www.findmykol.com/kol/sherleen-chen/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"sherleen-chen","name":"Sherleen Chen","credential":"MD","specialty":"Ophthalmology","specialty_raw":"Ophthalmology","therapeutic_area":"Ophthalmology","therapeutic_areas":["Ophthalmology"],"institution":"AbbVie","institution_url":"https://www.findmykol.com/institution/abbvie","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1528059383","orcid":"0000-0003-1254-4171","openalex":"A5012609950"},"summary":"Sherleen Chen is an Ophthalmology physician affiliated with AbbVie. OpenAlex indexes 30 publications with 1,036 citations (h-index 14).","overview":null,"focus":{"indications":[],"research_topics":["Ophthalmology"]},"scholarship":{"works_count":30,"cited_by_count":1036,"h_index":14,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":5,"program_years":{"first":2021,"last":null},"rows_total":8,"shown":3,"withheld":5,"rows":[{"payer":"Dompe US, Inc.","program_year":2025,"amount_usd":119.86,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1528059383"},{"payer":"Apellis Pharmaceuticals, Inc.","program_year":2025,"amount_usd":117.83,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1528059383"},{"payer":"SUN PHARMACEUTICAL INDUSTRIES INC.","program_year":2024,"amount_usd":114.3,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1528059383"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1528059383","source":"payments"},"prescribing":{"data_year":2024,"areas_total":5,"areas_shown":3,"areas":[{"area":"Sensory organs","share_pct":63.2,"classes_total":6,"classes":[{"class":"Prostaglandin Analog","setting":"prescribed","share_pct":25,"drugs":[{"name":"Latanoprost","share_pct":94},{"name":"Lumigan","share_pct":6}],"max_beneficiaries":null},{"class":"Corticosteroid","setting":"prescribed","share_pct":22.3,"drugs":[{"name":"Prednisolone Acetate","share_pct":100}],"max_beneficiaries":198}]},{"area":"Anti-infectives","share_pct":17.1,"classes_total":2,"classes":[{"class":"Fluoroquinolone Antibacterial","setting":"prescribed","share_pct":15.7,"drugs":[{"name":"Moxifloxacin","share_pct":100}],"max_beneficiaries":134},{"class":"Macrolide","setting":"prescribed","share_pct":1.4,"drugs":[{"name":"Erythromycin","share_pct":100}],"max_beneficiaries":null}]},{"area":"Cardiovascular","share_pct":7.7,"classes_total":1,"classes":[{"class":"Beta blocker","setting":"prescribed","share_pct":7.7,"drugs":[{"name":"Timolol Maleate","share_pct":100}],"max_beneficiaries":43}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":33,"shown":5,"withheld":28,"matched_by":"OpenAlex author record","recent":[{"title":"DOP014 Efficacy and safety up to 3 years of risankizumab maintenance treatment in patients with moderately to severely active ulcerative colitis: interim results from phase 3 COMMAND open-label extension study","year":2025,"journal":"Journal of Crohn s and Colitis","source_url":"https://doi.org/10.1093/ecco-jcc/jjae190.0053","status":"verified"},{"title":"DOP099 Prolonged Pharmacodynamic Effects of Risankizumab Following Withdrawal in Patients with Moderately to Severely Active Ulcerative Colitis","year":2025,"journal":"Journal of Crohn s and Colitis","source_url":"https://doi.org/10.1093/ecco-jcc/jjae190.0138","status":"verified"},{"title":"OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study","year":2024,"journal":"Journal of Crohn s and Colitis","source_url":"https://doi.org/10.1093/ecco-jcc/jjad212.0006","status":"verified"},{"title":"The Small Pupil","year":2024,"source_url":"https://doi.org/10.1201/9781003524038-22","status":"verified"},{"title":"Steroid Response Following Dropless Cataract Surgery Using Subconjunctival Triamcinolone","year":2023,"journal":"Clinical ophthalmology","source_url":"https://doi.org/10.2147/opth.s426200","status":"verified"}],"source":"works"},"contact":{"address_1":"243 CHARLES ST","city":"Boston","state":"MA","zip":"021143002","phone":"617-573-3529","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1528059383","source":"identity"},"similar":[{"name":"Markus P. Kummer","slug":"markus-kummer","institution":"AbbVie","url":"https://www.findmykol.com/kol/markus-kummer","json_url":"https://www.findmykol.com/kol/markus-kummer/profile.json"},{"name":"Knut P. H. Biber","slug":"knut-biber","institution":"AbbVie","url":"https://www.findmykol.com/kol/knut-biber","json_url":"https://www.findmykol.com/kol/knut-biber/profile.json"},{"name":"Helga Lorenz","slug":"helga-lorenz","institution":"AbbVie","url":"https://www.findmykol.com/kol/helga-lorenz","json_url":"https://www.findmykol.com/kol/helga-lorenz/profile.json"},{"name":"H. Küpper","slug":"h-kupper","institution":"AbbVie","url":"https://www.findmykol.com/kol/h-kupper","json_url":"https://www.findmykol.com/kol/h-kupper/profile.json"},{"name":"Emily Chew","slug":"emily-chew","institution":"National Eye Institute","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/emily-chew","json_url":"https://www.findmykol.com/kol/emily-chew/profile.json"},{"name":"Robert Weinreb","slug":"robert-weinreb","institution":"University of California San Diego","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/robert-weinreb","json_url":"https://www.findmykol.com/kol/robert-weinreb/profile.json"},{"name":"Harry Quigley","slug":"harry-quigley","institution":"Johns Hopkins University School of Medicine","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/harry-quigley","json_url":"https://www.findmykol.com/kol/harry-quigley/profile.json"},{"name":"Joel Schuman","slug":"joel-schuman","institution":"Wills Eye Hospital","specialty":"Ophthalmology","url":"https://www.findmykol.com/kol/joel-schuman","json_url":"https://www.findmykol.com/kol/joel-schuman/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":5,"publications":28}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2007-07-08","collected_at":"2026-11-03T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}